A pirinixic acid derivative (LP105) inhibits murine 5-lipoxygenase activity and attenuates vascular remodelling in a murine model of aortic aneurysm

British Journal of Pharmacology

Volumn 163, Issue 8, 2011, Pages 1721-1732

  Revermann, M ^a,b   Mieth, A ^a   Popescu, L ^a   Paulke, A ^a   Wurglics, M ^a   Pellowska, M ^a   Fischer, A S ^a   Steri, R ^a   Maier, T J ^a   Schermuly, R T ^c   Geisslinger, G ^a   Schubert Zsilavecz, M ^a   Brandes, R P ^a   Steinhilber, D ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MEDICAL FACULTY MANNHEIM HEIDELBERG UNIVERSITY   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

5 lipoxygenase; Angiotensin II; aortic aneurysm; arachidonic acid

Indexed keywords

14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; ARACHIDONATE 5 LIPOXYGENASE; EPOXIDE HYDROLASE; LP 105; PIRINIXIC ACID DERIVATIVE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN SYNTHASE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ANEURYSM; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME METABOLISM; HEART RATE; IC 50; LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ANGIOTENSIN II; ANIMALS; AORTA; AORTIC ANEURYSM; ARACHIDONATE 5-LIPOXYGENASE; CARDIOTONIC AGENTS; CARDIOVASCULAR SYSTEM; CELL LINE; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; EPOXIDE HYDROLASES; INJECTIONS, SUBCUTANEOUS; INTRAMOLECULAR OXIDOREDUCTASES; LIPOXYGENASE INHIBITORS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRIMIDINES;

EID: 79960907537     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01321.x     Document Type: Article

References (38)

1. Ahluwalia N, Lin AY, Tager AM, Pruitt IE, Anderson TJ, Kristo F, et al,. (2007). Inhibited aortic aneurysm formation in BLT1-deficient mice. J Immunol 179: 691-697. (Pubitemid 46986588)
2. Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, et al,. (2007). Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 104: 9018-9023. (Pubitemid 47175429)
3. Ai D, Pang W, Li N, Xu M, Jones PD, Yang J, et al,. (2009). Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy. Proc Natl Acad Sci USA 106: 564-569.
4. Alexander SP, Mathie A, Peters JA, (2009). Guide to receptors and channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1): S1-S254.
5. Barbosa-Sicard E, Fromel T, Keseru B, Brandes RP, Morisseau C, Hammock BD, et al,. (2009). Inhibition of the soluble epoxide hydrolase by tyrosine nitration. J Biol Chem 284: 28156-28163.
6. Cao RY, Adams MA, Habenicht AJ, Funk CD, (2007). Angiotensin II-induced abdominal aortic aneurysm occurs independently of the 5-lipoxygenase pathway in apolipoprotein E-deficient mice. Prostaglandins Other Lipid Mediat 84: 34-42. (Pubitemid 47069932)
7. Chen Q, (2009). Nordihydroguaiaretic acid analogues: their chemical synthesis and biological activities. Curr Top Med Chem 9: 1636-1659.
8. Daugherty A, Manning MW, Cassis LA, (2000). Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605-1612. (Pubitemid 30390311)
9. Daugherty A, Manning MW, Cassis LA, (2001). Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 134: 865-870. (Pubitemid 33016158)
10. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W, (1996). The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384: 39-43.
11. Evans JF, Ferguson AD, Mosley RT, Hutchinson JH, (2008). What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 29: 72-78.
12. Fleming I, (2007). Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 82: 60-67. (Pubitemid 44880162)
13. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD, (2007). Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 73: 227-236. (Pubitemid 44937188)
14. Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, et al,. (2005). Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 11: 861-866. (Pubitemid 41161118)
15. Holmes DR, Wester W, Thompson RW, Reilly JM, (1997). Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 25: 810-815. (Pubitemid 27227676)
16. Kehrer JP, Biswal SS, La E, Thuillier P, Datta K, Fischer SM, et al,. (2001). Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem J 356: 899-906. (Pubitemid 32588464)
17. Koeberle A, Zettl H, Greiner C, Wurglics M, Schubert-Zsilavecz M, Werz O, (2008). Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J Med Chem 51: 8068-8076.
18. Kristo F, Hardy GJ, Anderson TJ, Sinha S, Ahluwalia N, Lin AY, et al,. (2010). Pharmacological inhibition of BLT1 diminishes early abdominal aneurysm formation. Atherosclerosis 210: 107-113.
19. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA, (1997). Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406-3410.
20. Liu JY, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang SH, et al,. (2010). Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 79: 880-887.
21. Ma J, Liang S, Wang Z, Zhang L, Jiang J, Zheng J, et al,. (2010). ROCK pathway participates in the processes that 15-hydroxyeicosatetraenoic acid (15-HETE) mediated the pulmonary vascular remodeling induced by hypoxia in rat. J Cell Physiol 222: 82-94.
22. Mittra S, Sangle G, Tandon R, Sharma S, Roy S, Khanna V, et al,. (2007). Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema? Br J Pharmacol 150: 480-487. (Pubitemid 46280645)
23. Naruhn S, Meissner W, Adhikary T, Kaddatz K, Klein T, Watzer B, et al,. (2010). 15-hydroxyeicosatetraenoic acid is a preferential peroxisome proliferator-activated receptor beta/delta agonist. Mol Pharmacol 77: 171-184.
24. Peters-Golden M, Henderson WR Jr, (2007). Leukotrienes. N Engl J Med 357: 1841-1854.
25. Popescu L, Rau O, Bottcher J, Syha Y, Schubert-Zsilavecz M, (2007). Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists. Arch Pharm (Weinheim) 340: 367-371. (Pubitemid 47121193)
26. Radmark O, Werz O, Steinhilber D, Samuelsson B, (2007). 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 32: 332-341. (Pubitemid 47021417)
27. Revermann M, Barbosa-Sicard E, Dony E, Schermuly RT, Morisseau C, Geisslinger G, et al,. (2009). Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats. J Hypertens 27: 322-331.
28. Revermann M, Schloss M, Barbosa-Sicard E, Mieth A, Liebner S, Morisseau C, et al,. (2010). Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice. Arterioscler Thromb Vasc Biol 30: 909-914.
29. Riccioni G, Capra V, D'Orazio N, Bucciarelli T, Bazzano LA, (2008). Leukotriene modifiers in the treatment of cardiovascular diseases. J Leukoc Biol 84: 1374-1378. (Pubitemid 352774472)
30. Rizas KD, Ippagunta N, Tilson MD III, (2009). Immune cells and molecular mediators in the pathogenesis of the abdominal aortic aneurysm. Cardiol Rev 17: 201-210.
31. Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP, et al,. (2006). Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103: 13646-13651. (Pubitemid 44413961)
32. Tabas I, (2010). Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol 10: 36-46.
33. Ulu A, Davis BB, Tsai HJ, Kim IH, Morisseau C, Inceoglu B, et al,. (2008). Soluble epoxide hydrolase inhibitors reduce the development of atherosclerosis in apolipoprotein e-knockout mouse model. J Cardiovasc Pharmacol 52: 314-323.
34. Wang M, Lee E, Song W, Ricciotti E, Rader DJ, Lawson JA, et al,. (2008). Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation 117: 1302-1309. (Pubitemid 351365673)
35. Werz O, Steinhilber D, (1996). Selenium-dependent peroxidases suppress 5-lipoxygenase activity in B-lymphocytes and immature myeloid cells. The presence of peroxidase-insensitive 5-lipoxygenase activity in differentiated myeloid cells. Eur J Biochem 242: 90-97. (Pubitemid 26386360)
36. Werz O, Greiner C, Koeberle A, Hoernig C, George S, Popescu L, et al,. (2008). Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J Med Chem 51: 5449-5453.
37. Wymann MP, Schneiter R, (2008). Lipid signalling in disease. Nat Rev Mol Cell Biol 9: 162-176. (Pubitemid 351158917)
38. Zhao L, Moos MP, Grabner R, Pedrono F, Fan J, Kaiser B, et al,. (2004). The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat Med 10: 966-973. (Pubitemid 39273738)